Johnson & Johnson Highlights the Real-World Study of Erleada (Apalutamide) for Treating Metastatic Castration-Sensitive Prostate Cancer at ECOP 2024
Shots:
- J&J highlighted the real-world study of Erleada in mCSPC patients (n=4,000) at ECOP 2024, showing improved OS at 24mos. vs enzalutamide
- Study followed the US FDA’s real-world evidence guidelines and involved 1,800 Erleada as well as 1,909 enzalutamide patients with mCSPC who initiated treatment from Dec 2018 to Dec 2023
- The analysis showed 23% reduced death risk at 24mos. in patients who started Erleada vs enzalutamide and 87.6% survival rate in the Erleada cohort aligns with the 82.4% survival rate in the P-III (TITAN) study. TITAN study also showed improved OS with Erleada + ADT vs ADT alone in primary analysis at 22.7mos. median follow-up & final analysis at 44mos. median follow-up
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News: Janssen Receives EC's Approval for Expanded Use of Erleada (apalutamide) to Treat Metastatic Hormone-Sensitive Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
